Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $50.40.

TWST has been the topic of a number of research analyst reports. The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird reduced their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim restated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th.

Twist Bioscience Trading Up 4.1%

Shares of Twist Bioscience stock opened at $31.57 on Friday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -9.34 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $27.12 and a 12-month high of $60.90. The firm's 50-day moving average price is $34.33 and its two-hundred day moving average price is $41.95.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 936 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the transaction, the chief financial officer now owns 106,018 shares in the company, valued at approximately $3,154,035.50. The trade was a 0.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer now owns 240,783 shares in the company, valued at $7,163,294.25. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,012 shares of company stock worth $817,752 in the last ninety days. Company insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Several hedge funds have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock valued at $789,000 after acquiring an additional 219 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. Hillsdale Investment Management Inc. increased its stake in shares of Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after acquiring an additional 300 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C increased its stake in shares of Twist Bioscience by 1.7% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after acquiring an additional 403 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.